drugset
drugset / Trial / NCT06057571

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

NCT06057571 ↗

Phase 2 Active not recruiting 50 enrolled TransThera Sciences (Nanjing), Inc.
NaSingle-groupOpen-labelTreatment

Summary

A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.

Timeline

Start
2023-11-17
Primary completion
2025-07-27
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinengotinib Small molecule 10 mg Oral

Indications

cholangiocarcinoma